Sagimet Biosciences Announces Positive Phase 3 Extension Results; Suspends ATM

What Happened
Sagimet Biosciences Inc. (SGMT) filed an 8‑K on September 30, 2026 reporting positive 52‑week results from the Phase 3 ASC40‑304 open‑label extension trial of denifanstat in moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd. The company also updated an investor slide presentation (Exhibit 99.1) to be used in investor meetings and issued a press release with the trial results (Exhibit 99.2). Separately, Sagimet suspended and terminated the at‑the‑market (ATM) prospectus supplement for its Series A common stock under the Sales Agreement with Leerink Partners LLC (dated August 14, 2025); the Sales Agreement itself remains in effect.

Key Details

• Filing date: September 30, 2026.
• Clinical: Positive 52‑week results from Phase 3 ASC40‑304 open‑label extension of denifanstat (Ascletis BioScience Co. Ltd., China).
• Financing: ATM prospectus supplement terminated effective September 30, 2026; no sales of common stock under the Sales Agreement will occur until a new prospectus, prospectus supplement, or registration statement is filed.
• Materials: Updated investor presentation (Exhibit 99.1) and press release announcing results (Exhibit 99.2) were attached to the 8‑K.

Why It Matters
Positive long‑term Phase 3 extension data can strengthen the clinical case for denifanstat and may support regulatory or commercial activities in China through Sagimet’s license partner, which is material to the company’s product prospects. At the same time, termination of the ATM prospectus supplement limits Sagimet’s immediate ability to raise capital through at‑the‑market equity sales until new offering documents are filed, which is relevant for near‑term financing flexibility. Investors should note the concrete clinical update and the temporary change in equity financing capacity; the underlying Sales Agreement with Leerink remains available to resume sales once a new prospectus or registration is in place.